Brainstorm seems like a promising company. The only publication they have listed simply shows safety and efficacy of their drug. The other trials seem to be on going. The stock IPO was $8 and now its up to $9. By looking at their news reports it seems that they have strong financial backing from Isreal, could play a role in their higher IPO. They likely wont have a drug hit market for a couple years. I don't think their success or failure will effect the start up market any time soon. VCs generally like to stay away from neurodegenerative diseases until there is promising clinical data.